NCT02475655 - Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

February 18, 2018

Study Completion Date

April 4, 2018

Conditions

HIV Infections

Interventions

DRUG

Ruxolitinib

10 mg orally twice daily for 5 weeks

Trial Locations (14)

Weill Cornell Chelsea CRS, New York

Weill Cornell Uptown CRS, New York

University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester

Penn Therapeutics, CRS, Philadelphia

Alabama CRS, Birmingham

Vanderbilt Therapeutics (VT) CRS, Nashville

Case Clinical Research Site, Cleveland

Cincinnati Clinical Research Site, Cincinnati

Northwestern University CRS, Chicago

UCLA CARE Center CRS, Los Angeles

UCSD Antiviral Research Center CRS, San Diego

Ucsf Hiv/Aids Crs, San Francisco

Washington University Therapeutics (WT) CRS, St Louis

The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH